NCT01038752 - Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

November 30, 2012

Study Completion Date

May 31, 2013

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Suramin Drug:Docetaxel Drug: Carboplatin

Suramin dosage will be determined by nomogram and administered over 30 minutes. Suramin is followed by docetaxel (56 mg/m2, administered over 1 hour), followed by carboplatin (dosage calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).

DRUG

Placebo Drug: Docetaxel Drug: Carboplatin

Placebo (100 ml of 0.9% sodium chloride or 5% dextrose in water) will be administered over 30 minutes, followed by docetaxel (75 mg/m2, administered over 1 hour), followed by carboplatin (dose calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).

Trial Locations (2)

23298

Virginia Commonwealth University Massey Cancer Center, Richmond

60612

John H Stroger Jr Hospital of Cook County, Chicago